NEW YORK, NY April 18, 2024 – NeuroEnergy Ventures, Inc. today announced the anticipated launch of Neuridan™, an innovative new product designed to meet distinctive brain nutrition needs in certain people with mild cognitive impairment (MCI) and mild-to-moderate Alzheimer’s Disease.
Based on decades of research, Neuridan has been developed to supply a specific nutritional need in people with impaired glucose metabolism in the brain. Administered under medical supervision, it can be taken alongside standard medications used to treat neurodegenerative conditions and those affecting glucose metabolism in the brain.
“Neuridan is a true advance,” said George E. Stagnitti, CEO of NeuroEnergy Ventures, Inc. “With Neuridan, people living with MCI and Alzheimer’s Disease have a new way to provide energy to their brains that the normal diet alone cannot.”
Specially formulated and processed, Neuridan is an orally-consumed medical food. Neuridan is intended for the dietary management of patients with limited or impaired capacity, and who have other special medically determined nutrient requirements that cannot be met by modification of the normal diet alone.
The Science Behind Neuridan™
Neuridan™ is a ketogenic glyceryl 3-hydroxybutyrate ester (ketone bodies with a glycerin backbone). When ingested, Neuridan safely delivers highly purified ketones for brain nutrition without involving the liver. The brain can use these ketones for energy when normal glucose-based nutrition is insufficient or compromised – such as in certain types of MCI and Alzheimer’s Disease – and in a way that has been shown to be safe.
Unlike other methods for boosting ketones in the body, Neuridan is easy to consume, tolerate, and manage. For convenience and consumer flexibility, Neuridan can be added to other foods and beverages.
The main ingredient of Neuridan has been determined to be GRAS (Generally Recognized As Safe) for nutritional management of patients with certain neurodegenerative diseases, including Alzheimer’s Disease, and those suffering from non-penetrative traumatic brain injuries.
Initial availability of Neuridan is anticipated to begin in the fourth quarter of 2024 with a limited rollout in select U.S. locations. Neuridan is expected to be made available by primary care physicians or neurologists in conjunction with guidance to address cognition and memory loss as part of a treatment plan that may also include dietary and exercise regimens.
About NeuroEnergy Ventures, Inc.
Based in the United States, NeuroEnergy Ventures was founded in 2016 as a scientific philanthropy. From the beginning, the firm’s focus has been on research and development of ketone-based foods, and related compounds for people with reduced neuronal glucose metabolism established and recognized by the medical community based on decades-long research.
In addition to the anticipated launch of Neuridan™, NeuroEnergy Ventures is exploring additional applications for its innovative approach to ketone-based brain nutrition.
The firm holds a large portfolio of patents covering its food and related biomedical innovations. These include 38 granted patents and 23 pending patent applications for glyceride esters used in the treatment of diseases associated with reduced neuronal metabolism of glucose and other medical indications.
Contact
NeuroEnergy Ventures, Inc.
641 Lexington Avenue, 14th Floor
New York, NY 10022
+1 (212) 328-9524
gstagnitti@neuro-energy.com
neuro-energy.com
